ArvinasARVN
Recorded

Arvinas 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration51 minParticipants15

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good day, and thank you for standing by. Welcome to the Arvinas Q3 2026 earnings call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising that your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker, Jeff Boyle with investor relations.

Jeff BoyleVP of Investor Relations

Please go ahead. Good morning, everyone, and thank you for joining us.

Jeff BoyleVP of Investor Relations

Earlier today, we issued a press release with our third quarter 2026 financial results, which is available in the investors and media section of our website at arvinas.com. Joining us on the call today, we have Randy Teel, our President and CEO, Angela Cacace, our Chief Scientific Officer, and Andrew Saik, our Chief Financial Officer. Before we begin, I will remind you that today's discussion contains forward-looking statements that involve risks, uncertainties, and assumptions. These risks and uncertainties are outlined in today's press release and in the company's recent filing with the Securities and Exchange Commission, which I urge you to read. Our actual results may differ materially from what is discussed on today's call.

Jeff BoyleVP of Investor Relations

A replay of this call, as well as today's press release and an updated corporate deck, will be available on the investor and media section of our website. Now I will turn the call over to Randy Teel.

Randy TeelPresident and CEO

Randy? Thanks, Jeff, and good morning, everyone.

Randy TeelPresident and CEO

I will start by reiterating our commitment to prioritizing investments in programs where emerging evidence supports the greatest potential for value creation, letting the data drive our capital allocation decisions. If we execute on that commitment, we believe Arvinas can create important medicines for patients and significant long-term value for shareholders. We are entering an important period of clinical milestones that we believe will further define both our individual programs and the broader potential of our platform. During the call, I will provide an overview of our portfolio and plans. Angela will share additional information on our clinical programs, and Andrew will give an overview of our finances and approach to capital allocation. I will begin with ARV-393, our oral BCL6 degrader, and a great example of a program with strong scientific rationale for differentiation.

Randy TeelPresident and CEO

BCL6 is a key driver of lymphoma biology, and we believe our ability to degrade this classically undruggable transcription factor could offer a differentiated approach to treating B and T-cell lymphomas. We see the potential for our BCL6 degrader to become a backbone of future treatment strategies as both a monotherapy and in combination with standards of care. This could include reducing, delaying, or sparing chemotherapy for patients. During the quarter, as we continued enrolling the monotherapy and combination cohorts of our phase I trial, we submitted our initial monotherapy dose escalation data for presentation at the ASH Conference in December. This will be the first of 2 data readouts for the program, with the second readout expected in mid-2027. The first disclosure will focus on patients with T-cell lymphomas, where there are limited treatment options available.

Randy TeelPresident and CEO

These data support our belief that ARV-393 is an active degrader of BCL6, with the potential to be very competitive as we continue development. The data we share in 2027 will include a greater proportion of patients dosed at levels expected to reach efficacious exposures in B-cell lymphomas, more robust data on durability, and initial data from the combination with glofitamab, the first of our planned combination cohorts. I'll move next to ARV-027, our first-in-class oral androgen receptor degrader targeting the root cause of spinal bulbar muscular atrophy, or SBMA, also known as Kennedy's disease. This degrader targets the polyglutamine repeat androgen receptor, or polyQ AR, which is found in patients with this genetically defined disease. SBMA is an X-linked disease where the polyQ AR aggregates and gains a toxic function, driving progressive muscle weakness and functional decline.

Randy TeelPresident and CEO

By eliminating the toxic accumulation of polyQ AR in muscle, we have the potential to create the first-ever disease-modifying therapy for patients with this rare neuromuscular disease. The SBMA program is advancing through multiple dose cohorts in its phase I trial, and we intend to share initial data from the healthy volunteer cohorts in the first half of 2027. We also intend to begin dosing patients with SBMA in the first half of 2027. If successful, we believe the phase I data for this program will significantly de-risk the program, and we will begin discussions with health authorities about initiating a registration-enabling trial. I'll turn next to our first immuno-oncology degrader, ARV-6723. By impacting the immune system beyond the ability of current IO therapies, we believe this first-in-class oral HPK1 degrader could become an important treatment for patients in 3 distinct ways. First, following a checkpoint inhibitor.

Randy TeelPresident and CEO

Second, in combination with a checkpoint inhibitor. And third, in indications where checkpoint inhibitors have not shown benefit. Based on promising monotherapy and combination preclinical data, we initiated a phase I trial in the third quarter. Monotherapy dose escalation is ongoing, and we plan to initiate dosing in combination with pembrolizumab in the first half of 2027. HPK1 is a protein that dampens multiple parts of the cancer immunity cascade, and we believe that by removing it, our degrader has the potential to harness the body's natural tumor immunity to fight cancer. We look forward to providing initial data from this program in the second half of 2027. Rounding out our clinical progress, I'll next provide a brief update on current plans for our LRRK2 degrader, ARV-102. Following scientific advice from CHMP, we're now prioritizing the initiation of a phase I-B trial in the E.U. and the U.K.

Randy TeelPresident and CEO

Next month, we plan to submit clinical trial applications for a phase I-B trial in patients with progressive supranuclear palsy, or PSP. Trial initiation is targeted for 2027. In parallel, we are in consultation with Japanese health authorities to inform potential development in Japan as part of a long-term global clinical strategy. In the U.S., we continue discussions with the FDA about the ongoing clinical hold of our IND. Our current objective is now to include U.S. sites in future trials after completing the phase I-B trial in the E.U. and the U.K. Last month, we reported additional and novel biomarker findings from our phase I trial, including improvements in an objective and quantifiable measure of impaired eye movement associated with Parkinson's disease.

Randy TeelPresident and CEO

The totality of evidence from our phase I trial strengthens our belief in the potential of LRRK2 degradation to create novel clinical breakthroughs for patients with devastating neurodegenerative diseases. What is common across all of our programs is the scientific premise that by degrading the proteins that cause disease, we can create transformational treatments to address unmet patient need. We are pursuing targets where removing the protein has the potential to change the treatment landscape and improve outcomes for patients. The progress we are making today is laying the foundation for the next wave of innovation at Arvinas and advancing our mission of delivering transformative medicines to patients. With that, I will turn the call over to Angela.

Angela CacaceChief Scientific Officer

Angela? Thank you, Randy. As we approach key pipeline milestones, I will highlight how our preclinical data support our differentiated science, inform clinical development, and position our portfolio to deliver value.

Angela CacaceChief Scientific Officer

Starting with ARV-393, our strategy is to establish its potential both as a single agent and in combinations that could expand treatment options for patients with lymphoma. We have shown strong single-agent activity in preclinical DLBCL models with enhanced activity, including complete tumor regressions when combined with chemotherapy, biologics, and investigational oral agents. The results with R-CHOP and bispecific antibodies support the combination strategy we are advancing in the clinic. The first phase I disclosure will provide an early look at safety and tolerability, drug exposure, target engagement, and anti-tumor activity. These initial cohorts were treated at doses below those predicted to be efficacious in preclinical DLBCL models.

Angela CacaceChief Scientific Officer

Even at these early dose levels, we have observed responses across NHL subtypes, including B and T-cell lymphomas. The disclosure will focus on safety, PK, and PD from all patients, and preliminary efficacy from early cohorts in patients with T-cell lymphoma, where treatment options remain limited. These data will help guide dose selection and expansion plans. Our next update, expected in mid-2027, will include more patients with B-cell lymphoma treated at doses in the predicted efficacious range with longer follow-up, along with initial combination data with glofitamab. Turning to our polyQ AR degrader, ARV-027, our phase I study is designed to establish safety and tolerability and determine whether the drug degrades the androgen receptor in skeletal muscle. Importantly, we are seeing profound preclinical activity in muscle strength and endurance, two of the most fundamental manifestations of SBMA disease progression.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day